TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
Objective response rate across all 29 participants was 32.1%; Favorable disease control rate (92.9%) across all participants was observed
Data suggest that the combination of Ixo-V and bevacizumab may expand therapeutic options for Claudin 6-positive patients in both the platinum-resistant and platinum-sensitive settings
Pivotal